Kura Oncology Files 8-K

Ticker: KURA · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1422143

Kura Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyKura Oncology, INC. (KURA)
Form Type8-K
Filed DateDec 20, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-k, regulatory-filing

TL;DR

Kura Oncology filed an 8-K on 12/20 for an event on 12/16. Details to follow.

AI Summary

Kura Oncology, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 16, 2024. The filing is a current report and does not specify the exact nature of the event but is categorized under 'Other Events' and 'Financial Statements and Exhibits'.

Why It Matters

This filing indicates a material event has occurred for Kura Oncology, Inc., requiring public disclosure. Investors should review the full filing for details on the nature of the event and its potential impact.

Risk Assessment

Risk Level: medium — An 8-K filing signifies a material event, but without specific details, the risk level is moderate until the content is analyzed.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing for Kura Oncology, Inc. on December 16, 2024?

The provided text does not specify the exact event, only that it is categorized under 'Other Events' and 'Financial Statements and Exhibits'.

When was this 8-K filing submitted to the SEC?

The filing was submitted on December 20, 2024.

What is Kura Oncology, Inc.'s principal executive office address?

The principal executive offices are located at 12730 High Bluff Drive, Suite 400, San Diego, CA 92130.

What is Kura Oncology, Inc.'s IRS Employer Identification Number?

The IRS Employer Identification Number is 61-1547851.

Under which sections of the 8-K form is this filing categorized?

This filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'.

Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-12-20 16:07:00

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Kura Oncology, Inc. 2023 Inducement Option Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kura Oncology, Inc. Date: December 20, 2024 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing